|
Carmona-Bayonas A, Calderon C, Hernandez R, Fernandez Montes A, Castelo B, Ciria-Suarez L, Antonanzas M, Rogado J, Pacheco-Barcia V, Asensio Martinez E, Ivars A, Ayala de la Pena F, Jimenez-Fonseca P. Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy. NPJ Breast Cancer. 2021 Jul 13;7(1):92. doi: 10.1038/s41523-021-00296-8. PubMed PMID: 34257315; PubMed Central PMCID: PMC8277774.
AÑO: 2021; IF: 3.307
|
34257315
|
Calderon C, Jimenez-Fonseca P, Hernandez R, Munoz MDM, Martinez de Castro E, Higuera O, Ghanem I, Castelo B, Rogado J, Carmona-Bayonas A. Prospective Study Comparing Clinicians' and Cancer Patients' Estimates of Risk of Relapse and Toxicity with Adjuvant Chemotherapy. Cancer Invest. 2021 Sep;39(8):589-596. doi: 10.1080/07357907.2021.1948561. Epub 2021 Jul 7. PubMed PMID: 34182858.
AÑO: 2021; IF: 2.368
|
|
Viudez A, Crespo G, Gomez Dorronsoro ML, Arozarena I, Marin-Mendez JJ, Custodio A, Benavent M, Goni S, Garcia-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, Lopez C, Jimenez-Fonseca P, San Vicente BL, Gonzalez-Borja I, Sevilla I, Hernandez-Garcia I, Carmona-Bayonas A, Capdevila J, Perez-Sanz J, Garcia-Carbonero R, Perez-Ricarte L, Llanos M, Vera R, De Jesus Acosta A. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology. 2021 Jan;21(1):215-223. doi: 10.1016/j.pan.2020.12.009. Epub 2020 Dec 19. PubMed PMID: 33358592.
AÑO: 2021; IF: 3.977
|
|
Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-Garcia MI, Lorenzo I, Diaz JA, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol. 2021 Oct;23(10):2046-2056. doi: 10.1007/s12094-021-02608-7. Epub 2021 Jun 9. PubMed PMID: 34109562; PubMed Central PMCID: PMC8390421.
AÑO: 2021; IF: 3.34
|
|
Valenti V, Carmona-Bayonas A, Jimenez-Fonseca P, Salazar R. Olaratumab-induced Biomarker Modulation in Sarcomas-Letter. Mol Cancer Ther. 2021 Oct;20(10):2093. doi: 10.1158/1535-7163.MCT-21-0413. No abstract available. PubMed PMID: 34607901.
AÑO: 2021; IF: 6.009
|